{"filing":{"accession_number":"0001213900-26-098405","cik":"0001841330","ticker":"KTTAW","company_name":"Pasithea Therapeutics Corp.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ea0304934-8k_pasithea.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026098405/ea0304934-8k_pasithea.htm"},"events":[{"id":32370,"run_id":29738,"accession_number":"0001213900-26-098405","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This is a clear disclosure of shareholder voting results from Pasithea Therapeutics' Annual Meeting held on September 9, 2026. The filing reports the outcomes of three proposals: election of two Class III directors (Proposal 1), ratification of CBIZ as independent auditor (Proposal 2), and approval of a reverse stock split authorization (Proposal 3), with detailed vote tallies for each. The reverse stock split authorization is particularly material as it grants the Board discretion to implement a 1:2 to 1:20 reverse split, which typically signals delisting risk or financial distress at small-cap issuers.","company_name":"Pasithea Therapeutics Corp.","ticker":"KTTAW","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35530,"accession_number":"0001213900-26-098405","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder voting results from Pasithea Therapeutics' Annual Meeting held on September 9, 2026. The filing reports the outcomes of three proposals: election of two Class III directors (Proposal 1), ratification of CBIZ as independent auditor (Proposal 2), and approval of a reverse stock split authorization (Proposal 3), with detailed vote tallies for each. The reverse stock split authorization is particularly material as it grants the Board discretion to implement a 1:2 to 1:20 reverse split, which typically signals delisting risk or financial distress at small-cap issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:28:00.628171+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35530,"accession_number":"0001213900-26-098405","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder voting results from Pasithea Therapeutics' Annual Meeting held on September 9, 2026. The filing reports the outcomes of three proposals: election of two Class III directors (Proposal 1), ratification of CBIZ as independent auditor (Proposal 2), and approval of a reverse stock split authorization (Proposal 3), with detailed vote tallies for each. The reverse stock split authorization is particularly material as it grants the Board discretion to implement a 1:2 to 1:20 reverse split, which typically signals delisting risk or financial distress at small-cap issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:28:00.628171+00:00","company_name":"Pasithea Therapeutics Corp.","ticker":"KTTAW","filing_date":"2026-09-09"}]}